Nuformix (NFX) Share Price, News & Analysis

Company Overview

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

Key Stats

• Today's Range: 0.10 to 0.15
• 50-Day Range: 0.08 to 0.15
• 52-Week Range: 0.04 to 0.30
• Volume: 135.32 million shs
• Average Volume: 52.44 million shs
• Market Capitalization: £1.60 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: GBX 293
• Consensus Rating: Buy

Nuformix Stock Analysis - MarketRank™

Nuformix scored higher than 44% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nuformix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nuformix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nuformix is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nuformix is -3.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nuformix has a P/B Ratio of 0.24. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NFX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nuformix does not currently pay a dividend.

Dividend Growth

Nuformix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NFX.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.54

News Sentiment

Nuformix has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nuformix this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nuformix insiders have not sold or bought any company stock.

Percentage Held by Insiders

12.44% of the stock of Nuformix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.12% of the stock of Nuformix is held by institutions.

NFX Stock Analysis - Frequently Asked Questions

How have NFX shares performed this year?

Nuformix's stock was trading at GBX 0.05 at the beginning of 2025. Since then, NFX stock has increased by 188.9% and is now trading at GBX 0.13.
View the best growth stocks for 2025 here.

How were Nuformix's earnings last quarter?

Nuformix plc (LON:NFX) announced its earnings results on Friday, May, 2nd. The company reported $0.03 EPS for the quarter.

How do I buy shares of Nuformix?

Shares of NFX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of Nuformix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nuformix investors own include Allena Pharmaceuticals (ALNA), Rolls-Royce Holdings plc (RR), UK Oil & Gas (UKOG), 88 Energy (88E), Ampliphi Biosciences (APHB), Argo Blockchain (ARB) and Ardelyx (ARDX).

Company Calendar

• Last Earnings: 5/02/2025
• Today: 5/03/2025

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: LON:NFX
• Previous Symbol: LON:LVRT
• CIK: N/A
• Web: www.levrett.com
• Phone: 44 1223 423 667
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 293
• High Stock Price Target: GBX 293
• Low Stock Price Target: GBX 293
• Potential Upside/Downside: +225,284.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-383,402.73
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5.68%
• Return on Assets: -17.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.12
• Quick Ratio: 3.35

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: GBX 0.04 per share
• Price / Cash Flow: 3.55
• Book Value: GBX 0.54 per share
• Price / Book: 0.24

Miscellaneous

• Outstanding Shares: 1,231,809,091
• Free Float: N/A
• Market Cap: £1.60 million
• Optionable: Not Optionable
• Beta: 1.22